39 studies found for:    " November 17, 2010":" December 17, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" November 17, 2010":" December 17, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Conditions: HIV;   HIV Infection
Intervention: Biological: SB-728-T
2 Active, not recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
3 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
4 Completed Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
5 Completed
Has Results
Two Approaches to Routine HIV Testing in a Hospital Emergency Department
Condition: HIV Infections
Interventions: Procedure: Oral HIV screening;   Procedure: Fingerstick HIV screening
6 Unknown  Improving Antiretroviral Medication Adherence Among HIV-infected Youth: Phase I
Condition: HIV Infection
Intervention:
7 Completed Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
8 Completed The Influence of GINkGo Biloba on the Pharmacokinetics of the UGT Substrate raltEgraviR (GINGER)
Conditions: HIV Infections;   Depression;   Mild Cognitive Impairment
Interventions: Drug: raltegravir single dose;   Drug: ginkgo biloba multiple dose
9 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
10 Active, not recruiting A Randomized Controlled Trial of the Bruthas Project
Condition: HIV Infection
Interventions: Behavioral: Bruthas Project;   Behavioral: Standard HIV Testing and Counseling
11 Unknown  Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
12 Recruiting Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
Conditions: HIV;   AIDS;   Opioid Dependence;   Drug Dependence
Intervention: Drug: Extended-Release Naltrexone
13 Recruiting Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Conditions: HIV Infection;   Recurrent Anal Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Anal Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IV Verrucous Carcinoma of the Larynx;   Stage IV Verrucous Carcinoma of the Oral Cavity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: carboplatin;   Drug: paclitaxel
14 Completed Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans
Conditions: Metabolic Syndromes;   HIV Infection
Intervention:
15 Unknown  Impact of Raltegravir on the Viral Reservoirs
Condition: HIV Infection
Intervention:
16 Completed Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight
Condition: HIV Infection
Intervention: Drug: Nevirapine
17 Active, not recruiting The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
Condition: HIV Infections
Intervention: Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
18 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
19 Completed Addressing Psychosocial Needs and HIV Risk in Indian MSM
Conditions: HIV/STI Risk;   HIV/STI Incidence
Intervention: Behavioral: Behavioral intervention
20 Active, not recruiting
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: PI;   Drug: RTV;   Drug: NRTIs

   Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results    Last Page
Indicates status has not been verified in more than two years